Literature DB >> 3542110

A toxicity and pharmacokinetic study in man of the hypoxic-cell radiosensitiser RSU-1069.

A Horwich, S B Holliday, J M Deacon, M J Peckham.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3542110     DOI： 10.1259/0007-1285-59-708-1238

Source DB:  PubMed          Journal:  Br J Radiol        ISSN： 0007-1285            Impact factor:   3.039


× No keyword cloud information.
  8 in total

1.  Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.

Authors:  M I Walton; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 2.  Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.

Authors:  J C Bremner
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

3.  Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).

Authors:  M Binger; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Pharmacokinetics and cytotoxicity of RSU-1069 in subcutaneous 9L tumours under oxic and hypoxic conditions.

Authors:  K H Wong; C J Koch; C A Wallen; K T Wheeler
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

5.  Distribution of pimonidazole and RSU 1069 in tumour and normal tissues.

Authors:  L M Cobb; J Nolan; S A Butler
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

6.  Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.

Authors:  D R Newell; S S Burtles; B W Fox; D I Jodrell; T A Connors
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

7.  Cytotoxic effect of RB 6145 in human tumour cell lines: dependence on hypoxia, extra- and intracellular pH and drug uptake.

Authors:  L D Skarsgard; D K Acheson; A Vinczan; B G Wouters; B E Heinrichs; D A Loblaw; A I Minchinton; D J Chaplin
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

8.  Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.

Authors:  D R Newell; K M Searle; N B Westwood; S S Burtles
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.